彭布罗利珠单抗
医学
肿瘤科
内科学
化疗
PD-L1
免疫疗法
癌症
作者
Byoung Chul Cho,Yi-Long Lung Cancer Wu,G. Lopes,Iveta Kudaba,Dariusz Mirosław Kowalski,H.Z. Turna,Gilberto de Castro,Christian Caglevic,L. Zhang,Bogusława Karaszewska,Константин Константинович Лактионов,Vichien Srimuninnimit,Igor Bondarenko,K. Kubota,L. Yin,J. Lin,F. Souza,Tony S.K. Mok
标识
DOI:10.1016/j.jtho.2021.01.143
摘要
In the KEYNOTE-042 study (NCT02220894), pembrolizumab significantly improved OS vs platinum-based chemotherapy as first-line treatment for locally advanced/metastatic NSCLC without sensitizing EGFR/ALK alterations with PD-L1 tumor proportion score (TPS) ≥1%. We present updated data from KEYNOTE-042 with >3 years follow-up from randomization, including an exploratory analysis of time to progression on next-line therapy (PFS-2). Outcomes in patients who completed 35 cycles of pembrolizumab and in those who received second-course treatment are also reported.
科研通智能强力驱动
Strongly Powered by AbleSci AI